Skye Bioscience, Inc. Common Stock (SKYE) — Cash Flow-to-Debt Ratio
Skye Bioscience, Inc. Common Stock (SKYE) has a Cash Flow-to-Debt Ratio of -0.82x as of March 2026, meaning its operating cash flow of $-8.56 Million could theoretically repay -1% of its total liabilities ($10.40 Million) in one year. Check SKYE capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Skye Bioscience, Inc. Common Stock Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Skye Bioscience, Inc. Common Stock across 14 annual periods. Also explore SKYE asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Skye Bioscience, Inc. Common Stock (2012–2025)
Year-by-year debt coverage analysis for Skye Bioscience, Inc. Common Stock. For market capitalisation and broader financial context, see SKYE market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -5.19x | $-43.06 Million | $8.29 Million | ▲ +5.1% |
| 2024 | -5.47x | $-25.24 Million | $4.61 Million | ▼ -451.9% |
| 2023 | -0.99x | $-13.95 Million | $14.07 Million | ▲ +5.7% |
| 2022 | -1.05x | $-12.74 Million | $12.12 Million | ▲ +35.2% |
| 2021 | -1.62x | $-6.47 Million | $3.99 Million | ▲ +40.5% |
| 2020 | -2.73x | $-6.05 Million | $2.22 Million | ▲ +34.5% |
| 2019 | -4.16x | $-6.03 Million | $1.45 Million | ▼ -1748.8% |
| 2018 | -0.23x | $-3.94 Million | $17.52 Million | ▲ +90.7% |
| 2017 | -2.43x | $-3.30 Million | $1.36 Million | ▼ -21.3% |
| 2016 | -2.00x | $-3.55 Million | $1.77 Million | ▼ -63.3% |
| 2015 | -1.23x | $-3.73 Million | $3.04 Million | ▲ +44.0% |
| 2014 | -2.19x | $-1.76 Million | $801.89K | ▼ -2650.6% |
| 2013 | -0.08x | $-14.49K | $182.15K | ▼ -117.9% |
| 2012 | 0.45x | $1.93K | $4.33K | — |